{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:58:44Z","timestamp":1767866324733,"version":"3.49.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.semnephrol.2025.151650","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:04:52Z","timestamp":1754406292000},"page":"151650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integration of Genetics Into the Design and Conduct of Clinical Trials in Nephrology"],"prefix":"10.1016","volume":"45","author":[{"given":"Justyna E.","family":"Ozimek-Kulik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas G.","family":"Larkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopi K.","family":"Rangan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh J.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.semnephrol.2025.151650_bib0001","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0002","unstructured":"A. Kottgen, E. Cornec-Le Gall, J. Halbritter, et al., Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Kidney Int, 101 (6), 2022, 1126\u20131141."},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151650_bib0003","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Groopman","year":"2019","journal-title":"N Engl J Med"},{"issue":"9931","key":"10.1016\/j.semnephrol.2025.151650_bib0004","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/S0140-6736(14)60659-0","article-title":"Rare inherited kidney diseases: challenges, opportunities, and perspectives","volume":"383","author":"Devuyst","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151650_bib0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151650_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae035","article-title":"Actioning the findings of hard endpoint clinical trials as they emerge in the realm of chronic kidney disease care: a review and a call to action","volume":"17","author":"Strippoli","year":"2024","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0007","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.ajkd.2023.12.014","article-title":"APOL1 nephropathy risk variants through the life course: a review","volume":"84","author":"Itoku","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/clinchem\/hvae190","article-title":"Polygenic risk scores in human disease","volume":"71","author":"Maamari","year":"2025","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0009","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1038\/s41467-019-11576-0","article-title":"Genome-wide association meta-analyses and fine-mapping elucidate pathways influencing albuminuria","volume":"10","author":"Teumer","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151650_bib0010","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-024-01714-w","article-title":"Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits","volume":"56","author":"Keaton","year":"2024","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151650_bib0011","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"issue":"10374","key":"10.1016\/j.semnephrol.2025.151650_bib0012","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.semnephrol.2025.151650_bib0013","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.0000000000000249","article-title":"The clinical utility of genetic testing in the diagnosis and management of adults with chronic kidney disease","volume":"34","author":"Dahl","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151650_bib0014","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.10.043","article-title":"The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov","volume":"63","author":"Inrig","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151650_bib0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.ekir.2021.12.037","article-title":"Detecting MUC1 variants in patients clinicopathologically diagnosed with having autosomal dominant tubulointerstitial kidney disease","volume":"7","author":"Okada","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"10433","key":"10.1016\/j.semnephrol.2025.151650_bib0016","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151650_bib0017","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00467-023-05877-2","article-title":"The urgent need for conducting clinical trials in pediatric nephrology globally","volume":"38","author":"Wightman","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0018","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2018050515","article-title":"Quantity and reporting quality of kidney research","volume":"30","author":"Chatzimanouil","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0019","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.1038\/s41598-021-85519-5","article-title":"Systematic differences in effect estimates between observational studies and randomized control trials in meta-analyses in nephrology","volume":"11","author":"Kimachi","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151650_bib0020","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1681\/ASN.2013121313","article-title":"The kidney research predicament","volume":"25","author":"Bryan","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.semnephrol.2025.151650_bib0021","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N E J Med"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0022","doi-asserted-by":"crossref","unstructured":"W.G. Herrington, N. Staplin, C. Wanner, et al., Empagliflozin in patients with chronic kidney disease, N E J Med, 388 (2), 2023, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"issue":"25","key":"10.1016\/j.semnephrol.2025.151650_bib0023","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N E J Med"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151650_bib0024","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41581-023-00756-3","article-title":"Increasing diversity and inclusion in nephrology clinical trials","volume":"19","author":"Young","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151650_bib0025","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.34067\/KID.0000000000000281","article-title":"Gender disparities in nephrology trials: a meta-analysis of enrollment trends between 2000 and 2021","volume":"4","author":"Soomro","year":"2023","journal-title":"Kidney360"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0026","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41467-024-45295-y","article-title":"Unraveling the epigenetic code: human kidney DNA methylation and chromatin dynamics in renal disease development","volume":"15","author":"Yan","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ki.2010.335","article-title":"Beyond genetics: epigenetic code in chronic kidney disease","volume":"79","author":"Dwivedi","year":"2011","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151650_bib0028","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/ijms17040451","article-title":"Epigenetic modifications in essential hypertension","volume":"17","author":"Wise","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151650_bib0029","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/14737167.2022.2020105","article-title":"Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective","volume":"22","author":"Tafuri","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13023-021-01901-6","article-title":"Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases","volume":"16","author":"Miller","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"26","key":"10.1016\/j.semnephrol.2025.151650_bib0031","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus Irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N E J Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2025.151650_bib0032","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2215\/CJN.03470410","article-title":"Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report","volume":"5","author":"Gulati","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151650_bib0033","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5500\/wjt.v11.i7.303","article-title":"Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: a systematic review and meta-analysis","volume":"11","author":"Boonpheng","year":"2021","journal-title":"World J Transplant"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0034","doi-asserted-by":"crossref","unstructured":"I. Kofotolios, M.J. Bonios, M. Adamopoulos, et al., The Han:SPRD rat: a preclinical model of polycystic kidney disease, Biomedicines, 12 (2), 2024, 362.","DOI":"10.3390\/biomedicines12020362"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-0716-0655-1_15","article-title":"Generating kidney organoids from human pluripotent stem cells using defined conditions","volume":"2155","author":"Howden","year":"2020","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0036","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1681\/ASN.0000000000000497","article-title":"Adaptive designs for clinical trials in nephrology","volume":"36","author":"Krishnasamy","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0037","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jama.2021.22507","article-title":"How to use and interpret the results of a platform trial: users\u2019 guide to the medical literature","volume":"327","author":"Park","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151650_bib0038","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151650_bib0039","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/j.seminoncol.2015.07.009","article-title":"The master protocol concept","volume":"42","author":"Redman","year":"2015","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151650_bib0040","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial","volume":"33","author":"Lopez-Chavez","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0041","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151650_bib0042","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/biostatistics\/kxac030","article-title":"Improved efficiency for cross-arm comparisons via platform designs","volume":"24","author":"Huang","year":"2023","journal-title":"Biostatistics"},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151650_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.21140","article-title":"Economic evaluation of cost and time required for a platform trial vs conventional trials","volume":"5","author":"Park","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"16","key":"10.1016\/j.semnephrol.2025.151650_bib0044","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151650_bib0045","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1171","article-title":"Researchers\u2019, regulators\u2019, and sponsors\u2019 views on pediatric clinical trials: a multinational study","volume":"138","author":"Joseph","year":"2016","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151650_bib0046","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","author":"Angus","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0047","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrd1927","article-title":"Bayesian clinical trials","volume":"5","author":"Berry","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"10.1016\/j.semnephrol.2025.151650_bib0048","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/sim.5326","article-title":"Practical guidelines for adaptive seamless phase II\/III clinical trials that use Bayesian methods","volume":"31","author":"Kimani","year":"2012","journal-title":"Statistics Med"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0049","doi-asserted-by":"crossref","first-page":"m115","DOI":"10.1136\/bmj.m115","article-title":"The adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design","volume":"369","author":"Dimairo","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151650_bib0050","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.0000000000000412","article-title":"Clinical trials for kidney disease in the era of personalized medicine","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"10.1016\/j.semnephrol.2025.151650_bib0051","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jama.2023.3322","article-title":"Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial","volume":"329","author":"Sundstr\u00f6m","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151650_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100691","article-title":"Participant perceptions in a long-term clinical trial of autosomal dominant polycystic kidney disease","volume":"5","author":"Amin","year":"2023","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151650_bib0053","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":". N Engl J Med."},{"issue":"13","key":"10.1016\/j.semnephrol.2025.151650_bib0054","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMra2302038","article-title":"Artificial intelligence and machine learning in clinical medicine","volume":"388","author":"Haug","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2021.106504","article-title":"Effects of dataset size and interactions on the prediction performance of logistic regression and deep learning models","volume":"213","author":"Bailly","year":"2022","journal-title":"Comp Methods Progr Biomed"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0056","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2020.03.002","article-title":"Logistic regression was as good as machine learning for predicting major chronic diseases","volume":"122","author":"Nusinovici","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151650_bib0057","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1007\/s00330-022-08832-1","article-title":"Correction to: Radiology artificial intelligence: a systematic review and evaluation of methods (RAISE)","volume":"32","author":"Kelly","year":"2022","journal-title":"Europ Radiol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0058","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13054-024-04860-z","article-title":"Use of artificial intelligence in critical care: opportunities and obstacles","volume":"28","author":"Pinsky","year":"2024","journal-title":"Crit Care"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0059","doi-asserted-by":"crossref","first-page":"l4923","DOI":"10.1136\/bmj.l4923","article-title":"Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study","volume":"366","author":"Loupy","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151650_bib0060","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.ajt.2023.07.004","article-title":"Validation of a prediction system for risk of kidney allograft failure in pediatric kidney transplant recipients: an international observational study","volume":"23","author":"Hogan","year":"2023","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0061","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s43856-022-00201-9","article-title":"Comparison of artificial intelligence and human-based prediction and stratification of the risk of long-term kidney allograft failure","volume":"2","author":"Divard","year":"2022","journal-title":"Commun Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151650_bib0062","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41591-024-03044-0","article-title":"Precision-guided treatment in high-risk pediatric cancers","volume":"30","author":"Lau","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151650_bib0063","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ajt.2024.04.015","article-title":"Exploring kidney allograft rejection: a proof-of-concept study using spatial transcriptomics","volume":"24","author":"Martin-Martin","year":"2024","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151650_bib0064","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151650_bib0065","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151650_bib0096","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Reports"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151650_bib0066","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0067","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.0000000000000022","article-title":"Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: randomized controlled trial","volume":"18","author":"Mekahli","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151650_bib0091","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0092","first-page":"2267","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0093","first-page":"1930","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017"},{"issue":"19","key":"10.1016\/j.semnephrol.2025.151650_bib0094","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0095","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100021","article-title":"Prescribed water intake in autosomal dominant polycystic kidney disease","volume":"1","author":"Rangan","year":"2022","journal-title":"NEJM Evidence"},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151650_bib0068","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrol Dialysis Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0069","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0070","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/s41467-022-32543-2","article-title":"PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression","volume":"13","author":"Lakhia","year":"2022","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.semnephrol.2025.151650_bib0071","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJM198704163161602","article-title":"Cysteamine therapy for children with nephropathic cystinosis","volume":"316","author":"Gahl","year":"1987","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151650_bib0072","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2215\/CJN.12321211","article-title":"A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety","volume":"7","author":"Langman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151650_bib0073","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000529471","article-title":"The CARDINAL trial of bardoxolone methyl in alport syndrome: when marketing interests prevail over patients clinical needs","volume":"147","author":"Ruggenenti","year":"2023","journal-title":"Nephron"},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151650_bib0074","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2215\/CJN.0000000000000458","article-title":"A randomized controlled clinical trial testing effects of lademirsen on kidney function decline in adults with Alport syndrome","volume":"19","author":"Gale","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2025.151650_bib0097","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2215\/CJN.02400222","article-title":"Effects of bardoxolone methyl in Alport syndrome","volume":"17","author":"Warady","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151650_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100855","article-title":"Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials","volume":"6","author":"Dixon","year":"2024","journal-title":"Kidney Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0084","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int"},{"issue":"13","key":"10.1016\/j.semnephrol.2025.151650_bib0099","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151650_bib0100","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.semnephrol.2025.151650_bib0075","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0076","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.00681","article-title":"Impact of a complement factor H gene variant on renal dysfunction, cardiovascular events, and response to ACE inhibitor therapy in type 2 diabetes","volume":"10","author":"Valoti","year":"2019","journal-title":"Front Genetics"},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151650_bib0077","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1093\/ndt\/gfq797","article-title":"Efficacy and safety of losartan in children with Alport syndrome: results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial","volume":"26","author":"Webb","year":"2011","journal-title":"Nephrol Dialysis Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151650_bib0078","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ndt\/gfae180","article-title":"Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport","volume":"40","author":"Gross","year":"2024","journal-title":"Nephrol Dialysis Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151650_bib0079","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2024","journal-title":"Nephrol Dialysis Transplant"},{"key":"10.1016\/j.semnephrol.2025.151650_bib0080","first-page":"542","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151650_bib0081","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151650_bib0082","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151650_bib0083","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151650_bib0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00240-023-01453-3","article-title":"Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)","volume":"51","author":"Goldfarb","year":"2023","journal-title":"Urolithiasis"},{"issue":"708","key":"10.1016\/j.semnephrol.2025.151650_bib0086","doi-asserted-by":"crossref","first-page":"eabc8226","DOI":"10.1126\/scitranslmed.abc8226","article-title":"Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome","volume":"15","author":"Ding","year":"2023","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2025.151650_bib0087","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.3390\/cells10123273","article-title":"Hematopoietic stem cell gene therapy for cystinosis: from bench-to-bedside","volume":"10","author":"Cherqui","year":"2021","journal-title":"Cells"},{"issue":"8003","key":"10.1016\/j.semnephrol.2025.151650_bib0088","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41586-023-06957-x","article-title":"Genomic data in the All of Us research program","volume":"627","author":"Bick","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151650_bib0089","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41431-020-00782-w","article-title":"CTRL\u2019: an online, dynamic consent and participant engagement platform working towards solving the complexities of consent in genomic research","volume":"29","author":"Haas","year":"2021","journal-title":"Eur J Human Gen"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151650_bib0090","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/17470161231152077","article-title":"Ethical considerations about the collection of biological samples for genetic analysis in clinical trials","volume":"19","author":"Galende-Dom\u00ednguez","year":"2023","journal-title":"Res Ethics"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929525000853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929525000853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:39:33Z","timestamp":1757677173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929525000853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0270929525000853"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2025.151650","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integration of Genetics Into the Design and Conduct of Clinical Trials in Nephrology","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2025.151650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151650"}}